摩根士丹利发表报告表示，将中国中药(00570.HK) 2025至2030年盈利预测下调10%至14%，以反映更多与中药配方颗粒降价相关的减值拨备；目标价由1.6元降至1.5元，维持“减持”评级。该行指，公司业绩持续逊于市场预期，且盈利质素有所下降。去年备受市场关注的交易终止事件，可能令投资者对公司管治的观感趋负面。该行料股份沽压将持续，因事件推动型的投资者很可能继续减持其剩余持股。(ss/w)(...
Source Link摩根士丹利发表报告表示，将中国中药(00570.HK) 2025至2030年盈利预测下调10%至14%，以反映更多与中药配方颗粒降价相关的减值拨备；目标价由1.6元降至1.5元，维持“减持”评级。该行指，公司业绩持续逊于市场预期，且盈利质素有所下降。去年备受市场关注的交易终止事件，可能令投资者对公司管治的观感趋负面。该行料股份沽压将持续，因事件推动型的投资者很可能继续减持其剩余持股。(ss/w)(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.